AstraZeneca (AZN)
(Delayed Data from NSDQ)
$75.17 USD
+0.14 (0.19%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $75.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AZN 75.17 +0.14(0.19%)
Will AZN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AZN
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Other News for AZN
AstraZeneca: A Triple Shot Of Income, Growth, And Value
Amgen’s Blincyto data send Cullinan higher
AstraZeneca price target raised by 600 GBp at UBS
AstraZeneca: Strong In A Weak Market
AstraZeneca price target raised by 500 GBp at Barclays